Pune-based Mylab Discovery Solutions has scaled up production and development of its COVID-19 pathodetect testing kit  with strategic funding under National Biopharma Mission of Department of Biotechnology (DBT).<br />'' <br />''The Secretary, Department of Biotechnology Dr Renu Swarup has said that in the fight against the current pandemic, having indigenous supplies of qualitative RT-PCR test kits was identified as a critical need in enhancing  testing ability. She said, scale-up of Mylab's pathodetect production was a step DBT took in that direction.<br />'' <br />''Currently, Mylab has a manufacturing capacity of two lakh  RT-PCR and 50 thousand  RNA tests. Mylab has obtained the approval of the Central Drugs Standard Control Organisation and ICMR to manufacture for NAT, HIV, HBV, HCV  and for detection of novel coronavirus. <br />'' <br />''<span style="color: #222222;">The company has recently launched a Molecular laboratory machine Compact XL that can manufacture various reagents as well as perform many molecular tests in a single machine unit. The machine will help  in setting up  Molecular Diagnostic labs in rural India as it eliminates huge infrastructure costs.</span><br />